Skip to content


  • Research
  • Open Access

Dual effects of human neutrophil peptides in a mouse model of pneumonia and ventilator-induced lung injury

Contributed equally
Respiratory Research201819:190

  • Received: 22 April 2018
  • Accepted: 20 August 2018
  • Published:



Pneumonia is a major cause of high morbidity and mortality in critically illness, and frequently requires support with mechanical ventilation. The latter can lead to ventilator-induced lung injury characterized by neutrophil infiltration. The cationic human neutrophil peptides (HNP) stored in neutrophils can kill microorganisms, but excessive amount of HNP released during phagocytosis may contribute to inflammatory responses and worsen lung injury. Based on our previous work, we hypothesized that blocking the cell surface purinergic receptor P2Y6 will attenuate the HNP-induced inflammatory responses while maintaining their antimicrobial activity in pneumonia followed by mechanical ventilation.


Plasma HNP levels were measured in patients with pneumonia who received mechanical ventilation and in healthy volunteers. FVB littermate control and HNP transgenic (HNP+) mice were randomized to receive P. aeruginosa intranasally. The P2Y6 antagonist (MRS2578) or vehicle control was given after P. aeruginosa instillation. Additional mice underwent mechanical ventilation at either low pressure (LP) or high pressure (HP) ventilation 48 h after pneumonia, and were observed for 24 h.


Plasma HNP concentration increased in patients with pneumonia as compared to healthy subjects. The bacterial counts in the bronchoalveolar lavage fluid (BALF) were lower in HNP+ mice than in FVB mice 72 h after P. aeruginosa instillation. However, upon receiving HP ventilation, HNP+ mice had higher levels of cytokines and chemokines in BALF than FVB mice. These inflammatory responses were attenuated by the treatment with MRS2578 that did not affect the microbial effects of HNP.


HNP exerted dual effects by exhibiting antimicrobial activity in pneumonia alone condition while enhancing inflammatory responses in pneumonia followed by HP mechanical ventilation. Blocking P2Y6 can attenuate the inflammation without affecting the antibacterial property of HNP. The P2Y6 receptor may be a novel therapeutic target in attenuation of the leukocyte-mediated excessive host responses in inflammatory lung diseases.


  • α-Defensins
  • Neutrophil
  • P2Y6 purinergic receptor
  • Bacteria clearance
  • Inflammation
  • Ventilator-induced lung injury


Bacterial pneumonia is a leading cause of acute respiratory distress syndrome (ARDS) and sepsis contributing to high mortality in the intensive care unit (ICU) [13]. During the onset of pneumonia neutrophils are recruited into the infected site and serve as the first line of innate host defense. In patients with pneumonia-associated respiratory dysfunction, mechanical ventilation is an essential supportive approach [4, 5], however, it can lead to ventilator-induced lung injury (VILI). VILI is characterized by neutrophil sequestration that is associated with uncontrolled inflammatory responses [6]. The designate biological consequences of neutrophil infiltration are two folds: 1) Eliminate the pathogens through phagocytosis, and 2) Generate inflammatory responses by production of oxygen radicals, proteolytic enzymes and release of antimicrobial peptides [7].

Pneumonia, ARDS and VILI shares a typical feature of neutrophil infiltration [810] acquired for phagocytosis of microbial intruders. Upon completion of phagocytosis the professional phagocytes release granules’ constituents that are strongly anti-microbial but may also cause damage by destructing surrounding tissue. Human neutrophils peptides (HNP) are the most abundant proteins in the azurophilic granules of neutrophils [11], and have been shown to induce inflammatory responses in human lung epithelial and endothelial cells [1216] and to cause lung injury in mouse models [14, 17] in addition to the microbicidal properties [18]. It is important for one to understand the exact role of HNP in the complex infectious and inflammatory conditions in order to maintain the protective effects while eliminating the unwanted immunological consequences.

HNP, also called α-defensins, are a family of cationic antimicrobial peptides against a broad arrays of pathogens [18]. HNP are synthesized during the promyelocyte stage of neutrophil maturation in bone marrow, and are transported to azurophil granules thus the amount of HNP stored in each granule remains unchanged in mature neutrophils [19], and HNP content is correlated with the number of leukocyte count [20]. Plasma levels of HNP released from neutrophils are under 50 ng/mL in healthy volunteers, but increase up to 4 folds in patients with bacterial infection [21]. HNP concentrations in bronchoalveolar lavage fluid (BALF) can be as high as 50-fold greater in ARDS patients than in healthy volunteers, and are correlated with IL-8 levels in BALF [20]. In patients with cystic fibrosis and mouse model of lung injury, we have previously demonstrated that HNP act on neutrophils and lung epithelium through the purinergic P2Y6 receptor [16] resulting in inflammatory responses.

In this study, we employed HNP+ transgenic mice to specifically examine the effects of HNP in the models of pneumonia and VILI to reproduce human clinical situations in which large amount of HNP is released [20, 21]. We tested the hypothesis that HNP are protective in pneumonia conditions but are harmful when excessively released in inflammatory conditions when inadequate mechanical ventilation is applied. Blocking P2Y6 receptor may attenuate the HNP-induced inflammatory responses without interrupting their antimicrobial activity, serving as a novel therapeutic approach in inflammatory lung diseases.


Plasma collection from pneumonia patients and healthy volunteers

The study was approved by the First Affiliated Hospital of Guangzhou Medical University Institutional Review Board (REC#201311), and written informed consent was obtained from all subjects. Patients with pneumonia admitted to the ICU were consecutively enrolled during October 2012–May 2014. Pneumonia diagnosis was based on clinical features (i.e., fever, dyspnea, increased or purulent secretions, dry and moist rales), chest infiltrates and positive sputum culture [22]. Exclusion criteria were those patients who received chemotherapy within 8 weeks prior to ICU admission. A total of 43 patients (> 18 years) with pneumonia who underwent invasive mechanical ventilation within 24 h of admission were included (Table 1). Age-matched healthy volunteers (n = 43) were recruited at physical check-up clinic serving as a control group. Blood samples were collected in EDTA tubes.
Table 1

Characteristics of patients with pneumonia and healthy subjects


Pneumonia (N = 43)

Healthy (N = 43)

Age (year)

63.8 ± 2.4

63.3 ± 0.7





18.1 ± 1.0


MV mode


44% (N = 19)



26% (N = 11)



14% (N = 6)



16% (N = 7)


VT (mL)

425.9 ± 6.9


PEEP (cmH2O)

6.9 ± 0.5



168.4 ± 10.3


WBC counts (× 109/L)

14.3 ± 1.2*

7.9 ± 0.3

Neutrophil counts (×109/L)

12.8 ± 1.1*

6.1 ± 0.3

Hemoglobin (g/L)

94.9 ± 2.8*

142.5 ± 1.8

PLT counts (×109/L)

209.6 ± 25.4*

253.9 ± 6.8

Creatinine (μmol/L)

113.8 ± 15.0


PCT (μg/L)

17.0 ± 6.8


HSCPR (mg/L)

62.0 ± 13.8


HNP concentration (ng/mL)

215.9 ± 39.1*

27.6 ± 2.0

Etiology of pneumonia

 Acinetobacter baumannii

35% (N = 15)


 Pseudomonas aeruginosa

14% (N = 6)


 Stenotrophomonas maltophilia

9% (N = 4)


 Staphylococcus haemolyticus

7% (N = 3)


 Klebsiella pneumoniae

7% (N = 3)


 Staphylococcus aureus

7% (N = 3)



21% (N = 9)




23% (N = 10)



35% (N = 15)



19% (N = 8)


 Renal failure

14% (N = 6)



2% (N = 1)


Corticosteroid treatment

37% (N = 16)


ICU stay (days)

28.9 ± 3.5


ICU mortality (%)



Note: Data shown are mean ± SEM. * p < 0.01 vs. Healthy

Abbreviations: A/C assist/control, APACHE acute physiology and chronic health evaluation, COPD chronic obstructive pulmonary disease, HNP human neutrophil peptides, HSCPR high-sensitivity C-reactive protein, ICU intensive care unit, IPPV intermittent positive pressure ventilation, MV mechanical ventilation, PCT procalcitonin, PEEP positive end expiratory pressure, PLT platelet, SIMV synchronized intermittent mandatory ventilation, VT tidal volume, WBC white blood cell

HNP endocytosis and IL-8 assays

Human lung epithelial cells (BEAS-2B, ATCC, Manassas, VA) were seeded at 2.5 × 105 cells/slide in chamber slides (Nunc, Naperville, IL), incubated for 30 min at 37 °C with FITC-labeled HNP (10 μg/mL). In additional chamber slides, BEAS-2B cells were treated for 30 min with 10 μM of reactive blue (a purinoceptor (P2Y) antagonist) [23], or suramin (a blocker for receptor-mediated endocytosis), prior to HNP stimulation (100 μg/mL). The cells were then fixed, stained with rhodamine-phalloidin (ThermoFisher Scientific), a high-affinity F-actin probe conjugated to the red-orange fluorescent dye for F-actin, and mounted for visualization.

In separate experiments, BEAS-2B cells or human monocytes (THP-1, ATCC, Manassas, VA) were treated with 10 μM of reactive blue or suramin 30 min before HNP stimulation (100 μg/mL) for 8 h. The supernatants were collected for measurement of IL-8 (MyBioSource, San Diego, CA).

P. aeruginosa culture

P. aeruginosa strain (ATCC 27853, Manassas, VA) was incubated overnight at 37 °C on 5% sheep blood agar plates, and colonies were picked and grown overnight in Tryptic Soy Broth (TSB, 5 mL per colony) at 37 °C at 170 rpm (MaxQTM 4500 orbital shaker, Thermo Scientific, Midland, ON, Canada). An overnight cultured bacteria was diluted into TSB, and incubated at a shaker for 2.5 h. The bacteria were then centrifuged at 8000 rpm (J2-MI Centrifuge, Beckman, USA) at 4 °C. After washes with phosphate buffered saline (PBS), the bacterial pellets were resuspended in PBS to a desired density (i.e., an OD value of 0.24 corresponded to 1 × 108 colony formation units (CFU)/mL) determined by spectrophotometry, then the bacterial solution was instilled after 6 times dilutions. The bacterial density used for instillation and collected in the BALF was determined by serial dilutions culture. The culture solution was spread over TSB-agar plates for colony count after incubation overnight.

Pneumonia and two-hit lung injury models

The animal protocols were approved by the Animal Care Committee of St. Michael’s Hospital. Male FVB mice (Jackson Laboratory, Bar Harbor, ME) served as background control and HNP transgenic (HNP+) mice [24] (St. Michael’s Hospital, Toronto, ON) of 10–12 weeks old were anesthesized by intraperitoneal injection of ketamine hydrochloride (50 mg/kg) and xylazine (10 mg/kg), and randomized into either pneumonia (P. aeruginosa, P.a.) or vehicle control (PBS) groups. Pneumonia was induced by intranasal instillation of 60 μL P. aeruginosa (106 CFU/mouse). This dose of P. aeruginosa was chosen based on a pilot study where 0.5 × 106, 1 × 106, 1.5 × 106, 2 × 106 and 5 × 106 CFU/mouse were used and 1 × 106 CFU/mouse resulted in localized bacterial colonization without significant induction of cytokine responses. This would leave a signal gap with respect to cytokine responses and the severity of lung injury between the models of P. aeruginosa alone and two-hit injury of P. aeruginosa followed by mechanical ventilation.

Following P. aeruginosa instillation 48 h later, the mice were either assigned to breathe spontaneously or to receive orotracheal intubation for mechanical ventilation with either a relative protective ventilator strategy of low pressure (LP) ventilation at peak inspiratory pressure (PIP) 10 cmH2O, positive end-expiratory pressure (PEEP) 3 cmH2O, respiratory rate (RR) 120 breaths/min, or a relative injurious ventilator strategy of high pressure (HP) ventilation at PIP 22 cmH2O (to cause overdistension), PEEP 0 cmH2O (to cause atelectrauma), RR 70 breaths/min under FiO2 of 0.5. Upon completion of 2-h mechanical ventilation, mice were weaned and housed in animal facility for 24 h.

Administration of P2Y6 receptor antagonist

MRS2578 (Sigma, St Louis, MO), a selective P2Y6 receptor antagonist, was intraperitoneally injected at a dose of 4 μL/g body weight from a 10 μM stock concentration 15 min after P. aeruginosa instillation. Since the half-life of MRS2578 is unknown, we chose to administer MRS2578 at 24 h and 48 h after the first dose, based on previous studies in mice where MRS2578 was effective for 24 h [2527]. This dose was chosen based on our pilot study testing a dose-dependent response to 10 μM or 20 μM of MRS2578 in HNP+ mice after established pneumonia. The triple doses of 10 μM were able to decrease neutrophil infiltration without induction of toxicity. The same volume of 1% DMSO was used to serve as a vehicle control. Based on our pilot studies, we estimated the sample size of 7/group would be sufficient in the present study by using PASS software assuming the expected standard deviation will be 20% of the mean between the groups, with 0.8 of power and α = 0.05. Considering the sample size (i.e., N = 5–8 mice/group) being used in other relevant studies [14, 2528], we finally chose to use 5 mice in PBS control groups, and 7 mice in pneumonia groups in both FVB and HNP+ strains.

Bacterial count, total and differential cell count and albumin in BALF

Upon completion of the study, tracheotomy was performed and a catheter (18G, BD Angiocath, Franklin Lakes, NJ) was inserted into the trachea. A microvessel clamp was used to clip the hilus of the left lung, the right lung was lavaged with three times of injection of 0.5 mL PBS from the catheter. The hilus of the right lung was then ligated and the right lung was excised. The clamp at the left lung was removed and paraformaldehyde was used to inflate the left lung from the catheter. The BALF was serially diluted and cultured for bacterial recovery and counting. The cell pellets were resuspended in PBS for cytospin analysis of cell differentiation. The albumin concentration in the BALF was measured with a mouse albumin ELISA kit (Abcam, Toronto, Ontario, Canada).

Measurement of HNP and cytokines/chemokines

The HNP levels were determined as previously described [14]. Multiple mouse cytokines and chemokines (TNF-α, IL-1β, IL-6, IL-10, MCP-1 and KC) were measured in BALF by multiplex immunoassay using a Mouse ProcartaPlex Panel (e-Bioscience/Affymetrix, Santa Clara, CA).

Lung histopathology

The left lung was inflated and fixed with 4% paraformaldehyde and embedded in paraffin. Sections (5 μm) were stained with hematoxylin and eosin (H&E). Lung injury scores were assessed by a pathologist in a blinded fashion using a previously described scoring system based on 8 pathological features: alveolar distention, alveolar collapse, perivascular hemorrhage, perivascular edema, alveolar hemorrhage, alveolar edema, membranes formation and neutrophils infiltration. Each parameter was graded from 0 to 3 [29].

Statistical analysis

All data are presented as mean ± SEM. The statistical analysis was performed using GraphPad Prism 6. For comparison between pneumonia patients and healthy control groups, the Mann–Whitney U test was used. In vitro study, two-way ANOVA followed by Tukey’s test or Holm-Sidak test was used for statistical comparisons to examine the effect of HNP on IL-8 production, and one-way ANOVA was used for comparisons between reactive blue, suramin and HNP group. Since multiple factors (i.e., mouse strains, bacteria, mechanical ventilation and MRS2578 treatment) were involved in vivo study, significant differences among multiple groups were examined using two-way ANOVA followed by Tukey’s test or Holm-Sidak test. The multiple t-tests were also performed in some comparisons that tended to be significantly different after multiple comparisons for two-way ANOVA. A p value < 0.05 is considered statistically significant.


Plasma HNP concentrations increased in patients with pneumonia

The demographic and clinical characteristics in patients with pneumonia and healthy subjects are shown in Table 1. There was no significant difference in age between pneumonia patients and healthy donors. Plasma HNP concentration as well as the peripheral white blood cell and neutrophil counts were significantly higher in patients with pneumonia than that in healthy subjects.

HNP endocytosis by lung epithelial cells

When human lung epithelial cells were incubated with FITC-labeled HNP, we observed HNP endocytosis associated with increased IL-8 production (Fig. 1a, d). Both HNP endocytosis and IL-8 production were inhibited by the use of reactive blue and suramin (Fig. 1a-e). The HNP-induced IL-8 production was also attenuated by pretreatment with reactive blue and suramin in the human THP-1 monocytes (Fig. 1f). These results provided us with strong rationale to test the use of P2Y6 inhibitor in vivo models (Fig. 2).
Fig. 1
Fig. 1

HNP binding to BEAS-2B cells through P2Y receptor family. BEAS-2B cells were incubated with FITC-HNP for 30 min (a). HNP are labeled in green and F-actin in red. HNP binding was inhibited by addition of Reactive Blue (RB), or Suramin (b and c) 30 min prior to FITC-HNP. Effect of HNP on IL-8 production. HNP (100 μg/mL) induce IL-8 production by BEAS-2B cells in a time-dependent manner (d). RB (10 μM) or suramin (10 μM) added 30 min prior to HNP administration attenuated IL-8 production in BEAS-2B cells (e) and human THP-1 monocytes (f) at 8 h. * p < 0.05 vs. control group analyzed by Holm-Sidak test; † p < 0.05 vs. HNP group at other three time points analyzed by Tukey’s test; ¶ p < 0.05 vs. HNP group analyzed by one-way ANOVA, respectively

Fig. 2
Fig. 2

Study design and groups. Mice were intranasal instilled with P. aeruginosa (1× 106 CFU) or PBS. The mice in two-hit groups were then underwent mechanical ventilation for 2 h at either low pressure (LP) or high pressure (HP). MRS2578 was administrated intraperitoneally 15 min, 24 h and 48 h after pneumonia

Effects of MRS2578 in model of pneumonia alone

HNP expression increased due to high neutrophil count in the HNP+ mice despite the fact that there was a similar neutrophil recruitment in both FVB control mice (with no HNP gene) and the HNP+ (with HNP transgene) mice in response to P. aeruginosa instillation. The plasma HNP levels were higher in the HNP+ mice especially in the pneumonia group (Fig. 3a, c). In the pneumonia alone conditions, the BALF bacterial counts were lower in the HNP+ mice than in the FVB mice (Fig. 3b), which was associated with neutrophil infiltration in the HNP+ mice (Fig. 3c, d). The administration of MRS2578 had no effect in bacterial count (Fig. 3b), but decreased lung injury score in the HNP+ mice and not in the FVB mice (Fig. 3d, f).
Fig. 3
Fig. 3

Effects of MRS2578 in pneumonia. Mice were intranasally instilled with P. aeruginosa (1× 106 CFU) or PBS. a HNP levels in bronchoalveolar lavage fluid (BALF) were measured 72 h later. In additional mice, MRS2578 or vehicle (DMSO) was administered intraperitoneally 15 min, 24 h and 48 h after bacterial instillation. Bacteria counts (b) and neutrophils (c) in the BALF were determined 72 h after bacterial instillation. d Lung histology (H&E) was obtained 72 h after bacterial instillation, Pulmonary edema (black arrow) and neutrophil infiltration (circle) were indicated. e Lung permeability was determined by albumin concentration in BALF. f Lung injury score. N = 7 per group in P. aeruginosa groups, N = 5 per group in PBS groups. * p < 0.05 vs. FVB at identical conditions analyzed by Holm-Sidak test; ¶ p < 0.05 vs. PBS at the identical conditions analyzed by Tukey’s test; # p < 0.05 vs. DMSO at identical conditions analyzed by Tukey’s test, respectively

Effects of MRS2578 in two-hit model of pneumonia followed by mechanical ventilation

The inflammatory response was attenuated to a similar level following the treatment with MRS2578 at either 10 μM or 20 μM in spontaneous breathing group and in the HP ventilated group after pneumonia in HNP+ mice (Fig. 4a-c). Based on this observation, 10 μM MRS2578 was used in the subsequent studies.
Fig. 4
Fig. 4

Effects of MRS2578 in HNP+ mice with pneumonia followed by mechanical ventilation. HNP+ mice were intranasally instilled with P. aeruginosa (1× 106 CFU) and then subjected to keep spontaneous breathing (SB) or mechanical ventilation with high pressure (HP) for 2 h. MRS2578 at 10 μM or 20 μM was administrated intraperitoneally 15 min, 24 h and 48 h after pneumonia. Total cell counts (a) and neutrophil counts (b) in bronchoalveolar lavage fluid (BALF) were determined. c Lung histology (H&E) was obtained 72 h after bacterial instillation. Neutrophil infiltration (circle) was indicated. N = 7 per group. * p < 0.05 vs. spontaneous breathing (SB) at identical conditions analyzed by Holm-Sidak test; † p < 0.05 vs. DMSO at identical conditions analyzed by Tukey’s test, respectively

After P. aeriginosa instillation and mechanical ventilation, the bacterial counts remained lower in HNP+ mice than in FVB mice, and the use of MRS2578 did not have any effect on bacterial count (Fig. 5a). The application of mechanical ventilation alone did not significantly affect neutrophil infiltration and albumin concentration in BALF (Fig. 5b, c). However, in the two-hit model an increase in inflammatory responses and lung permeability were observed especially in HNP+ mice (Fig. 5b, c). The histological analysis showed a trend of increased lung injury score in the HP ventilation groups as compared to the LP ventilation groups but the difference did not reach statistically significance (Figs. 5d and 6). A significant difference was reached in the two-hit injury model in HNP+ mice (Figs. 5b-d and 6).
Fig. 5
Fig. 5

Effects of MRS2578 in pneumonia followed by mechanical ventilation. Mice were intranasally instilled with P. aeruginosa (1× 106 CFU) or PBS and received MRS2578 or vehicle (DMSO) 15 min, 24 h and 48 h after pneumonia, and then subjected to mechanical ventilation with either low (LP) or high (HP) pressure for 2 h. Bacteria counts (a) and neutrophil counts (b) in bronchoalveolar lavage fluid (BALF) were determined. c Lung permeability was determined by albumin concentration in BALF. d Lung injury score. N = 7 per group in P. aeruginosa groups, N = 5 per group in PBS groups. * p < 0.05 vs. FVB at identical conditions analyzed by Holm-Sidak test; † p < 0.05 vs. LP at identical conditions analyzed by multiple t tests; ¶ p < 0.05 vs. PBS at the identical conditions analyzed by multiple t tests; # p < 0.05 vs. DMSO at identical conditions analyzed by Tukey’s test, respectively

Fig. 6
Fig. 6

Effects of MRS2578 on histological changes after two-hit lung injury. Mice were intranasally instilled with P. aeruginosa (1× 106 CFU) or PBS and received MRS2578 or vehicle (DMSO) 15 min, 24 h and 48 h after pneumonia, and then subjected to mechanical ventilation with either low (LP) or high (HP) pressure for 2 h. Lung histology (H&E) was obtained 72 h h after pneumonia. Pulmonary edema (black arrow) and neutrophil infiltration (circle) were indicated

The levels of the pro-inflammatory cytokines/chemokines including TNF-α, IL-1β, IL-6, MCP-1 and KC were significantly higher in the HNP+ pneumonia mice under HP ventilation than other groups (Fig. 7a-e). The administration of MRS2578 resulted in an attenuation of leukocyte infiltration and lung injury (Figs. 5b-d and 6) as well as cytokine responses (Fig. 7).
Fig. 7
Fig. 7

Effects of MRS2578 on production of cytokines/chemokines in two-hit lung injury. Mice were intranasally instilled with P. aeruginosa (1× 106 CFU) or PBS and received MRS2578 or vehicle (DMSO) 15 min, 24 h and 48 h after pneumonia, and then subjected to mechanical ventilation with either low (LP) or high (HP) pressure for 2 h. The bronchoalveolar lavage fluid (BALF) was collected 24 h after mechanical ventilation. The concentrations of 6 cytokines/chemokines were simultaneously determined by Luminex multiplex assays. N = 7 per group in P. aeruginosa groups, N = 5 per group in PBS groups. * p < 0.05 vs. FVB at identical conditions analyzed by Holm-Sidak test; † p < 0.05 vs. LP at identical conditions analyzed by Tukey’s test; ¶ p < 0.05 vs. PBS at the identical conditions analyzed by Tukey’s test; # p < 0.05 vs. DMSO at identical conditions analyzed by Tukey’s test, respectively


Our results demonstrated that HNP concentrations are significantly elevated in pneumonia patients with mechanical ventilation. The experimental studies revealed that HNP play a critical role in the host defense system against P. aeruginosa pneumonia, but can also contribute to excessive inflammatory responses in the VILI conditions.

The models of the P. aeruginosa induced-pneumonia used in the present study are highly relevant to clinical situations of ARDS [30, 31]. We observed that HNP+ mice had much lower bacterial count than FVB mice in pneumonia conditions. This observation is in agreement with the known mechanisms by which HNP exert antimicrobial properties by inducing membrane permeability through the interaction between the positively charged HNP and the negatively charged microorganisms [32, 33], and also inhibiting cell wall synthesis [34].

Although FVB mice do not produce endogenous neutrophil peptides or HNP [35], they do show response to exogenous stimulation with HNP [17, 36, 37]. A previous study has reported greater lung damage by disrupting the capillary-epithelial barrier in HNP+ mice than in wild-type mice after the HCl-induced lung injury [28], our study was to examine the effects in a more clinical relevant conditions of pneumonia followed by mechanical ventilation. The protective effects of HNP seen in the pneumonia alone condition have turned into deleterious effects during an overwhelming inflammatory situation under two-hit injury. There are several potential explanations for this finding. Firstly, it has been shown that HNP can induce neutrophil influx into the lung by producing chemokines in lung epithelial cells [12, 13, 17]. Secondly, we have previously demonstrated that HNP at high concentrations interact with neutrophils resulting in decreased phagocytic capacity of neutrophils [14]. Finally, overproduction of reactive oxygen species by HNP [38] might have likely contributes to excessive inflammatory responses. HNP interact with host cells through P2Y6 receptor signaling, the use of P2Y6 antisense oligonucleotide resulted in attenuation of the HNP-induced IL-8 production in ex vivo human lung epithelial cells [16], which is independent of the cationic property. Our results demonstrate that the administration of MRS2578, a selective inhibitor of P2Y6 receptor, was able to attenuate the HNP-mediated inflammatory responses (i.e. reduced levels of cytokines and chemokines) and lung injury during HP mechanical ventilation while maintaining the microbicidal activity. In the absence of HNP in FVB mice, the inflammatory responses persisted following pneumonia while administration of MRS2578 had no effect on the mechanical ventilation-induced inflammatory responses. These results further confirmed the involvement of P2Y6 receptor acts as a signal sensor for HNP [16] as well as a therapeutic target.

There are limitations in the present study. Our previous work focused on an in vitro study identifying P2Y6 signaling in lung epithelial cells [16]. The present study extended the previous by testing the P2Y signal in human monocytes and the P2Y6 specific inhibitor in vivo two-hit model combining pneumonia and mechanical ventilation in order to understand the protective and detrimental effects of HNP in different inflammatory conditions. However, our experimental data does not allow one to suggest a critical concentration of HNP that would distinct protective effects from impairment and thus the exact dosage of P2Y6 blockade in clinical conditions. The P2Y6 receptor is broadly distributed in all organ tissues in human and mice [39, 40]. Thus we did not examine the expression of P2Y6 receptor in our study. The scope of our study was to establish the linkage between HNP and P2Y6 receptor by application of MRS2578 in conditions of pneumonia and mechanical ventilation. Future studies maybe required to investigate the expression of P2Y6 receptor in different conditions such as pneumonia, mechanical ventilation and sepsis, respectively. It is worth noting that in addition to neutrophils, HNP can also be found in natural killer cells, T cells, and immature dendritic cells [18, 41, 42], although it was unlikely the case in our acute models with dominant innate immunoresponse as opposed to a prolonged adaptive response involving immune cells other than neutrophils. Furthermore, we have previously reported that HNP mediated endothelial-monocyte interaction, foam cell formation and platelet activation [15]. The results obtained from our two-hit model using controlled titration of P. aeruginosa followed by mechanical ventilation may not be directly translated into all human situations in which bacterial phenotypes and invasion factors are variable. The present study opens a new avenue to conduct more in-depth clinical studies by including patients with ARDS due to non-infectious and patients with pneumonia who are not under mechanical ventilation.


In summary, our results suggested that blocking P2Y6 receptor signaling can attenuate the neutrophils, specifically, the HNP-mediated inflammatory responses without impairing the antimicrobial properties of HNP in the two-hit model of pneumonia followed by mechanical ventilation. Thus targeting the P2Y6 signaling may provide a novel therapeutic strategy to reserve the endogenous antimicrobial effects while attenuating the unwanted inflammatory consequence of HNP in inflammatory lung diseases.




acute respiratory distress syndrome


Bronchoalveolar lavage fluid


Colony formation units


Hematoxylin and eosin


Human neutrophil peptides


HNP transgenic


High pressure


Intensive care unit


Low pressure


P. aeruginosa


Phosphate buffered saline


Positive end-expiratory pressure


Peak inspiratory pressure


Respiratory rate


Tryptic Soy Broth


Ventilator-induced lung injury



Not applicable.


This study was supported by National Natural Science Foundation of China (Grant No. 81490534 to NZ and HZ; 81490530 to NZ and HZ; 81370177 to HZ; 81361128003 to NZ and YL; the Chief Scientist Project of Yangcheng Scholar in Guangzhou (Grant No. 1201541642) to HZ; and Canadian institute of Health Research (CIHR) to HZ.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JZ, YH conducted the study, analyzed data and drafted the work. DI, SW, CS, AL, ML, JK and BH contributed to data acquisition, analysis and interpretation. NZ and KY interpreted the data. YL gathered clinical data and interpreted the data. XW and HZ guided study design and interpreted the data. JZ and HZ revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The clinical study was approved by the First Affiliated Hospital of Guangzhou Medical University Institutional Review Board (REC#201311), and written informed consent was obtained from all subjects. The animal protocols were approved by the Animal Care Committee of St. Michael’s Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150000, Heilongjiang, China
The State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, Guangdong, China
Keenan Research Center for Biomedical Science of St. Michael’s Hospital, Toronto, ON, M5B 1W8, Canada
Department of Critical Care Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin, 150000, Heilongjiang, China
Interdepartmental Division of Critical Care Medicine, Departments of Anesthesia and Physiology, University of Toronto, Toronto, ON, M5B 1T8, Canada


  1. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800.View ArticleGoogle Scholar
  2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.View ArticleGoogle Scholar
  3. Arthur LE, Kizor RS, Selim AG, van Driel ML, Seoane L. Antibiotics for ventilator-associated pneumonia. Cochrane Database Syst Rev. 2016;10:CD004267.PubMedGoogle Scholar
  4. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008;133:610–7.View ArticleGoogle Scholar
  5. Walden AP, Clarke GM, McKechnie S, Hutton P, Gordon AC, Rello J, et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care. 2014;18:R58.View ArticleGoogle Scholar
  6. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013;369:2126–36.View ArticleGoogle Scholar
  7. Mizgerd JP. Molecular mechanisms of neutrophil recruitment elicited by bacteria in the lungs. Semin Immunol. 2002;14:123–32.View ArticleGoogle Scholar
  8. Craig A, Mai J, Cai S, Jeyaseelan S. Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun. 2009;77:568–75.View ArticleGoogle Scholar
  9. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306:L217–30.View ArticleGoogle Scholar
  10. Choudhury S, Wilson MR, Goddard ME, O'Dea KP, Takata M. Mechanisms of early pulmonary neutrophil sequestration in ventilator-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol. 2004;287:L902–10.View ArticleGoogle Scholar
  11. Gabay JE, Almeida RP. Antibiotic peptides and serine protease homologs in human polymorphonuclear leukocytes: defensins and azurocidin. Curr Opin Immunol. 1993;5:97–102.View ArticleGoogle Scholar
  12. Vaschetto R, Grinstein J, Del Sorbo L, Khine AA, Voglis S, Tullis E, et al. Role of human neutrophil peptides in the initial interaction between lung epithelial cells and CD4+ lymphocytes. J Leukoc Biol. 2007;81:1022–31.View ArticleGoogle Scholar
  13. Syeda F, Liu HY, Tullis E, Liu M, Slutsky AS, Zhang H. Differential signaling mechanisms of HNP-induced IL-8 production in human lung epithelial cells and monocytes. J Cell Physiol. 2008;214:820–7.View ArticleGoogle Scholar
  14. Voglis S, Quinn K, Tullis E, Liu M, Henriques M, Zubrinich C, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med. 2009;180:159–66.View ArticleGoogle Scholar
  15. Quinn KL, Henriques M, Tabuchi A, Han B, Yang H, Cheng WE, et al. Human neutrophil peptides mediate endothelial-monocyte interaction, foam cell formation, and platelet activation. Arterioscler Thromb Vasc Biol. 2011;31:2070–9.View ArticleGoogle Scholar
  16. Khine AA, Del Sorbo L, Vaschetto R, Voglis S, Tullis E, Slutsky AS, et al. Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood. 2006;107:2936–42.View ArticleGoogle Scholar
  17. Zhang H, Porro G, Orzech N, Mullen B, Liu M, Slutsky AS. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion. Am J Physiol Lung Cell Mol Physiol. 2001;280:L947–54.View ArticleGoogle Scholar
  18. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–20.View ArticleGoogle Scholar
  19. Valore EV, Ganz T. Posttranslational processing of defensins in immature human myeloid cells. Blood. 1992;79:1538–44.PubMedGoogle Scholar
  20. Ashitani J, Mukae H, Arimura Y, Sano A, Tokojima M, Nakazato M. High concentrations of alpha-defensins in plasma and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Life Sci. 2004;75:1123–34.View ArticleGoogle Scholar
  21. Ihi T, Nakazato M, Mukae H, Matsukura S. Elevated concentrations of human neutrophil peptides in plasma, blood, and body fluids from patients with infections. Clin Infect Dis. 1997;25:1134–40.View ArticleGoogle Scholar
  22. American Thoracic S, Infectious Diseases Society of A. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.View ArticleGoogle Scholar
  23. Grobben B, Claes P, Roymans D, Esmans EL, Van Onckelen H, Slegers H. Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists. Br J Pharmacol. 2000;130:139–45.View ArticleGoogle Scholar
  24. Wu J, Han B, Fanelli V, Wen X, Huang Y, Luo A, et al. Distinctive Roles and Mechanisms of Human Neutrophil Peptides in Experimental Sepsis and Acute Respiratory Distress Syndrome. Crit Care Med. 2018. [Epub ahead of print].View ArticleGoogle Scholar
  25. Zhang Z, Wang Z, Ren H, Yue M, Huang K, Gu H, et al. P2Y(6) agonist uridine 5′-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment. J Immunol. 2011;186:5376–87.View ArticleGoogle Scholar
  26. Vieira RP, Muller T, Grimm M, von Gernler V, Vetter B, Durk T, et al. Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. Am J Respir Crit Care Med. 2011;184:215–23.View ArticleGoogle Scholar
  27. Riegel AK, Faigle M, Zug S, Rosenberger P, Robaye B, Boeynaems JM, et al. Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation. Blood. 2011;117:2548–55.View ArticleGoogle Scholar
  28. Bdeir K, Higazi AA, Kulikovskaya I, Christofidou-Solomidou M, Vinogradov SA, Allen TC, et al. Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier. Am J Respir Crit Care Med. 2010;181:935–46.View ArticleGoogle Scholar
  29. Ko SC, Zhang H, Haitsma JJ, Cheng KC, Li CF, Slutsky AS. Effects of PEEP levels following repeated recruitment maneuvers on ventilator-induced lung injury. Acta Anaesthesiol Scand. 2008;52:514–21.View ArticleGoogle Scholar
  30. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol. 1997;159:2858–66.PubMedGoogle Scholar
  31. Junkins RD, Carrigan SO, Wu Z, Stadnyk AW, Cowley E, Issekutz T, et al. Mast cells protect against Pseudomonas aeruginosa-induced lung injury. Am J Pathol. 2014;184:2310–21.View ArticleGoogle Scholar
  32. Kagan BL, Selsted ME, Ganz T, Lehrer RI. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A. 1990;87:210–4.View ArticleGoogle Scholar
  33. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest. 1989;84:553–61.View ArticleGoogle Scholar
  34. de Leeuw E, Li C, Zeng P, Li C, Diepeveen-de Buin M, Lu WY, et al. Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett. 2010;584:1543–8.View ArticleGoogle Scholar
  35. Eisenhauer PB, Lehrer RI. Mouse neutrophils lack defensins. Infect Immun. 1992;60:3446–7.PubMedPubMed CentralGoogle Scholar
  36. Ayabe T, Satchell DP, Pesendorfer P, Tanabe H, Wilson CL, Hagen SJ, et al. Activation of Paneth cell alpha-defensins in mouse small intestine. J Biol Chem. 2002;277:5219–28.View ArticleGoogle Scholar
  37. Ouellette AJ, Lualdi JC. A novel mouse gene family coding for cationic, cysteine-rich peptides. Regulation in small intestine and cells of myeloid origin. J Biol Chem. 1990;265:9831–7.PubMedGoogle Scholar
  38. Porro GA, Lee JH, de Azavedo J, Crandall I, Whitehead T, Tullis E, et al. Direct and indirect bacterial killing functions of neutrophil defensins in lung explants. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1240–7.View ArticleGoogle Scholar
  39. von Kugelgen I, Wetter A. Molecular pharmacology of P2Y-receptors. Naunyn Schmiedeberg's Arch Pharmacol. 2000;362:310–23.View ArticleGoogle Scholar
  40. Communi D, Paindavoine P, Place GA, Parmentier M, Boeynaems JM. Expression of P2Y receptors in cell lines derived from the human lung. Br J Pharmacol. 1999;127:562–8.View ArticleGoogle Scholar
  41. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 2000;96:3086–93.PubMedGoogle Scholar
  42. Rodriguez-Garcia M, Oliva H, Climent N, Garcia F, Gatell JM, Gallart T. Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3. J Leukoc Biol. 2007;82:1143–6.View ArticleGoogle Scholar


© The Author(s). 2018